Type 2 diabetes as an inflammatory disorder

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 1, 2003, Pages 36-41

  Sattar, Naveed ^a   Perry, Colin G ^b   Petrie, John R ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

Coronary heart disease; Cytokines; Inflammation; Type 2 diabetes; Vascular endothelium

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACUTE PHASE PROTEIN; ADIPONECTIN; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; METFORMIN; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; EXERCISE; HUMAN; INFLAMMATORY DISEASE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREDICTION; PROSPECTIVE STUDY; RISK ASSESSMENT; WEIGHT REDUCTION;

EID: 0042888889     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030010501     Document Type: Article

References (52)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
2. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001;47:28-30.
3. Rothkrantz-Kos S, Schmitz MP, Bekers O, Menheere PP, van Dieijen-Visser MP. High-sensitivity C-reactive protein methods examined. Clin Chem 2002;48:359-62.
4. Veselka J, Prochazkova S, Duchonova R et al. Relationship of C-reactive protein to presence and severity of coronary atherosclerosis in patients with stable angina pectoris or a pathological exercise test. Coron Artery Dis 2002;13:151-4.
5. Hill AG, Hill GL. Metabolic response to severe injury. Br J Sury 1998;85: 884-90.
6. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061-5.
7. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-8.
8. Wallace AM, McMahon AD, Packard CJ, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study. Circulation 2001;104:3052-6.
9. Cook DG, Mendall MA, Whincup PH et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000;149:139-50.
10. Kelly CCJ, Lyall H, Petrie JR, Gould GW, Connell JMC, Sattar N. Low-grade Chronic Inflammation in Women with PCOS. J Clin Endocrinol Metab 2001;86:2453-5.
11. Forouhi NG, Sattar N, McKeigue P. Relation of C-reactive protein to cardiovascular risk factors in Europeans and South Asians. Int J Obesity 2001;25:1327-31.
12. Chambers JC, Eda S, Bassett P et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104:145-50.
13. Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002;161:233-42.
14. Pannacciulli N, De Pergola G, Giorgino F, Giorgino R. A family history of Type 2 diabetes is associated with increased plasma levels of C-reactive protein in non-smoking healthy adult women. Diabet Med 2002;19:689-92.
15. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002;1105:1785-90.
16. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
17. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RF, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
18. Schmidt MI, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649-52.
19. Nakanishi N, Yoshida H, Matsuo Y, Suzuki K, Tatara K. White blood-cell count and the risk of impaired fasting glucose or Type II diabetes in middle-aged Japanese men. Diabetologia 2002;45:42-8.
20. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:455-61.
21. Pradhan AD, Manson JE, Rifai N, Buring JE, Ricker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
22. Barzilay JI, Abraham L, Heckbert SR et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:2384-9.
23. Freeman DJ, Norrie J, Caslake M et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-600.
24. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. The Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51: 1131-7.
25. Lindsay RS, Funahashi T, Hanson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-8.
26. Temelkova-Kurktschiev T, Siegert G, Bergmann S et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002;51: 743-9.
27. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes 1998;22:1145-58.
28. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
29. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5.
30. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000;85:1316-19.
31. Bastard JP, Jardel C, Bruckert E et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338-42.
32. Dovio A, Angeli A. Cytokines and type 2 diabetes mellitus. JAMA 2001;286:2233.
33. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181(suppl 3):S462-72.
34. Björntorp P. Fatty acids, hyperinsulinemia, and insulin resistance: which comes first? Curr Opin Lipidol 1994;5:166-74.
35. Steinberg HO, Baron AD, Steinberg H et al.: Vascular function, insulin resistance and fatty acids. Diabetologia 2002;45:623-34.
36. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997;349: 1391-2.
37. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliot H, McConnell JMC. Sensitive C-reactive protein and basal endothelial function. Clinical Science 2000;98:531-35.
38. van Exel E, Gussekloo J, de Craen AJ et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002;51:1088-92.
39. Gunnett CA, Heistad DD, Faraci FM. Interleukin-10 protects nitric oxide-dependent relaxation during diabetes: role of superoxide. Diabetes 2002; 51:1931-7.
40. Walder K, Kantham L, McMillan JS et al. Tanis: a link between type 2 diabetes and inflammation? Diabetes 2002;51:1859-66.
41. Kim JK, Kim YJ, Fillmore JJ et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108:437-46.
42. Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-19.
43. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-33.
44. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
45. Tuomilehto J, Lindström J, Erickson JG et al., for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med 2001;344:1343-50.
46. Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
47. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
48. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16.
49. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002;105:564-9.
50. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230-5.
51. Gullestad L, Aukrust P, Ueland T et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999;34:2061-7.
52. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679-84.